NCT02497521 The German ADPKD Tolvaptan Treatment Registry
| NCT ID | NCT02497521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Cologne |
| Condition | ADPKD (Autosomal Dominant Polycystic Kidney Disease) |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2015-11 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2015-11 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide "real-world" data on treatment management of patients with ADPKD.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * ADPKD proven by positive family history and evidence of renal cysts or diagnosed by treating physician * Presentation at our center for tolvaptan treatment indication, or tolvaptan treatment planned, or tolvaptan already started Exclusion Criteria: * Patients not capable of giving informed consent * End stage renal disease requiring renal replacement therapy * Patients receiving tolvaptan as "off-label use"
Contact & Investigator
Thomas Benzing, MD, Prof.
PRINCIPAL INVESTIGATOR
University Hospital of Cologne
Frequently Asked Questions
Who can join the NCT02497521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ADPKD (Autosomal Dominant Polycystic Kidney Disease). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02497521 currently recruiting?
Yes, NCT02497521 is actively recruiting participants. Contact the research team at roman-ulrich.mueller@uk-koeln.de for enrollment information.
Where is the NCT02497521 trial being conducted?
This trial is being conducted at Müllheim, Germany, Würzburg, Germany, Hanover, Germany, Cologne, Germany and 8 additional locations.
Who is sponsoring the NCT02497521 clinical trial?
NCT02497521 is sponsored by University of Cologne. The principal investigator is Thomas Benzing, MD, Prof. at University Hospital of Cologne. The trial plans to enroll 2,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.